Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: KYMR

Kymera Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for KYMR. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-3.25

Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-19 23:23 UTC.

What Kymera Therapeutics, Inc. does

This clinical-stage biopharmaceutical company develops oral medicines using targeted protein degradation, a technology that leverages the body's natural cellular recycling system to eliminate disease-causing proteins. The company focuses primarily on immunology targets, addressing immune-inflammatory diseases where current treatments either provide only symptomatic relief or rely on expensive, injectable biologics.

Summarized from Kymera Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-3.25

Revenue, margins & earnings

FY2021: net loss $100M on revenue $73M$73MFY2021FY2022: net loss $155M on revenue $47M$47MFY2022FY2023: net loss $147M on revenue $79M$79MFY2023FY2024: net loss $224M on revenue $47M$47MFY2024FY2025: net loss $311M on revenue $39M$39MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-01
  • 2026-10-01Chief Executive OfficerSale-8,230$949.7K
  • 2026-10-01Chief Executive OfficerSale-262$30.4K
  • 2026-10-01Chief Executive OfficerSale-7,601$869.8K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Kymera Therapeutics, Inc. do?

This clinical-stage biopharmaceutical company develops oral medicines using targeted protein degradation, a technology that leverages the body's natural cellular recycling system to eliminate disease-causing proteins.

When did KYMR last file with the SEC?

Kymera Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-25. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-19 23:23 UTC. This page is also available as JSON at /api/data?ticker=KYMR and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for KYMR and 5,000+ tickers.

Create a free account — keep KYMR
For your agent
GET /api/data?ticker=KYMR

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt